DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47:20–33

Article  PubMed  Google Scholar 

Clinical Development Success Rates and Contributing Factors 2011–2020 (2020) BIO, PharmaIntelligence, QLS Rep. https://www.bio.org/clinical-development-success-rates-and-contributing-factors-2011-2020

Vargas R, Egurbide-Sifre A, Medina L (2021) Organ-on-a-Chip systems for new drugs development. ADMET DMPK 9:111–141

Article  PubMed  PubMed Central  Google Scholar 

Booij TH, Price LS, Danen EHJ (2019) 3D cell-based assays for drug screens: challenges in imaging, image analysis, and high-content analysis. SLAS Discov 24:615–627

Article  CAS  PubMed  PubMed Central  Google Scholar 

Astashkina A, Mann B, Grainger DW (2012) A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol Ther 134:82–106

Article  CAS  PubMed  Google Scholar 

Senkowski W, Zhang X, Olofsson MH, Isacson R, Höglund U, Gustafsson M, Nygren P, Linder S, Larsson R, Fryknäs M (2015) Three-dimensional cell culture-based screening identifies the anthelmintic drug nitazoxanide as a candidate for treatment of colorectal cancer. Mol Cancer Ther 14:1504–1516

Article  CAS  PubMed  Google Scholar 

Wenzel C, Riefke B, Gründemann S, Krebs A, Christian S, Prinz F, Osterland M, Golfier S, Räse S, Ansari N, Esner M, Bickle M, Pampaloni F, Mattheyer C, Stelzer EH, Parczyk K, Prechtl S, Steigemann P (2014) 3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions. Exp Cell Res 323:131–143

Article  CAS  PubMed  Google Scholar 

Simian M, Bissell MJ (2017) Organoids: a historical perspective of thinking in three dimensions. J Cell Biol 216:31–40

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao N, Powell RT, Yuan X, Bae G, Roarty KP, Stossi F, Stremp M, Toneff MJ, Johnson HL, Mani SA, Jones P, Stephan CC, Rosen JM (2021) Morphological screening of mesenchymal mammary tumor organoids to identify drugs that reverse epithelial–mesenchymal transition. Nat Commun. https://doi.org/10.1038/s41467-021-24545-3

Article  PubMed  PubMed Central  Google Scholar 

Herpers B, Eppink B, James MI, Cortina C, Cañellas-Socias A, Boj SF, Hernando-Momblona X, Glodzik D, Roovers RC, van de Wetering M, Bartelink-Clements C, Zondag-van der Zande V, Mateos JG, Yan K, Salinaro L, Basmeleh A, Fatrai S, Maussang D, Lammerts van Bueren JJ, Chicote I, Serna G, Cabellos L, Ramírez L, Nuciforo P, Salazar R, Santos C, Villanueva A, Stephan-Otto Attolini C, Sancho E, Palmer HG, Tabernero J, Stratton MR, de Kruif J, Logtenberg T, Clevers H, Price LS, Vries RGJ, Batlle E, Throsby M (2022) Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. Nat Cancer 3:418–436

Article  CAS  PubMed  Google Scholar 

Calandrini C, van Hooff SR, Paassen I, Ayyildiz D, Derakhshan S, Dolman MEM, Langenberg KPS, van de Ven M, de Heus C, Liv N, Kool M, de Krijger RR, Tytgat GAM, van den Heuvel-Eibrink MM, Molenaar JJ, Drost J (2021) Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors. Cell Rep 36:109568

Article  CAS  PubMed  Google Scholar 

Low LA, Tagle DA (2017) Tissue chips-innovative tools for drug development and disease modeling. Lab Chip 17:3026–3036

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kühnl J, Tao TP, Brandmair K, Gerlach S, Rings T, Müller-Vieira U, Przibilla J, Genies C, Jaques-Jamin C, Schepky A, Marx U, Hewitt NJ, Maschmeyer I (2021) Characterization of application scenario-dependent pharmacokinetics and pharmacodynamic properties of permethrin and hyperforin in a dynamic skin and liver multi-organ-chip model. Toxicology. https://doi.org/10.1016/j.tox.2020.152637

Article  PubMed  Google Scholar 

Oleaga C, Bernabini C, Smith AST, Srinivasan B, Jackson M, McLamb W, Platt V, Bridges R, Cai Y, Santhanam N, Berry B, Najjar S, Akanda N, Guo X, Martin C, Ekman G, Esch MB, Langer J, Ouedraogo G, Cotovio J, Breton L, Shuler ML, Hickman JJ (2016) Multi-organ toxicity demonstration in a functional human in vitro system composed of four organs. Sci Rep 6:1–17

Article  Google Scholar 

Sung JH, Kam C, Shuler ML (2010) A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 10:446–455

Article  CAS  PubMed  Google Scholar 

Vernetti L, Gough A, Baetz N, Blutt S, Broughman JR, Brown JA, Foulke-Abel J, Hasan N, In J, Kelly E, Kovbasnjuk O, Repper J, Senutovitch N, Stabb J, Yeung C, Zachos NC, Donowitz M, Estes M, Himmelfarb J, Truskey G, Wikswo JP, Taylor DL (2017) Functional coupling of human microphysiology systems: intestine, liver, kidney proximal tubule, blood–brain barrier and skeletal muscle. Sci Rep 7:1–15

Google Scholar 

Rogers MT, Gard AL, Gaibler R, Mulhern TJ, Strelnikov R, Azizgolshani H, Cain BP, Isenberg BC, Haroutunian NJ, Raustad NE, Keegan PM, Lech MP, Tomlinson L, Borenstein JT, Charest JL, Williams C (2021) A high-throughput microfluidic bilayer co-culture platform to study endothelial-pericyte interactions. Sci Rep 11:1–14

Article  Google Scholar 

Trietsch SJ, Israëls GD, Joore J, Hankemeier T, Vulto P (2013) Microfluidic titer plate for stratified 3D cell culture. Lab Chip 13:3548–3554

Article  CAS  PubMed  Google Scholar 

Trietsch SJ, Naumovska E, Kurek D, Setyawati MC, Vormann MK, Wilschut KJ, Lanz HL, Nicolas A, Ng CP, Joore J, Kustermann S, Roth A, Hankemeier T, Moisan A, Vulto P (2017) Membrane-free culture and real-time barrier integrity assessment of perfused intestinal epithelium tubes. Nat Commun 8:1–7

Article  CAS  Google Scholar 

Ragelle H, Dernick K, Khemais S, Keppler C, Cousin L, Farouz Y, Louche C, Fauser S, Kustermann S, Tibbitt MW, Westenskow PD (2020) Human retinal microvasculature-on-a-chip for drug discovery. Adv Healthc Mater 9:1–10

Article  Google Scholar 

van Duinen V, Zhu D, Ramakers C, van Zonneveld AJ, Vulto P, Hankemeier T (2019) Perfused 3D angiogenic sprouting in a high-throughput in vitro platform. Angiogenesis 22:157–165

Article  PubMed  Google Scholar 

Vulto P, Podszun S, Meyer P, Hermann C, Manz A, Urban GA (2011) Phaseguides: a paradigm shift in microfluidic priming and emptying. Lab Chip 11:1596–1602

Article  CAS  PubMed  Google Scholar 

Iversen PW, Eastwood BJ, Sittampalam GS, Cox KL (2006) A comparison of assay performance measures in screening assays: signal window, Z′ factor, and assay variability ratio. J Biomol Screen 11:247–252

Article  CAS  PubMed  Google Scholar 

Zhang JH, Chung TDY, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67–73

Article  CAS  PubMed  Google Scholar 

Filippi-Chiela EC, Oliveira MM, Jurkovski B, Callegari-Jacques SM, da Silva VD, Lenz G (2012) Nuclear morphometric analysis (NMA): screening of senescence, apoptosis and nuclear irregularities. PLoS ONE. https://doi.org/10.1371/journal.pone.0042522

Article  PubMed  PubMed Central  Google Scholar 

Song M, Finley SD (2018) Mechanistic insight into activation of MAPK signaling by pro-angiogenic factors. BMC Syst Biol 12:1–17

Article  Google Scholar 

Allen E, Walters IB, Hanahan D (2011) Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 17:5299–5310

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, Foá R, Tafuri A, Cognetti F, Anichini A, Zupi G, Milella M (2009) Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 11:720–731

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung CH, Chang CH, Chen SS, Wang HH, Yen JY, Hsiao CJ, Wu NL, Chen YL, Huang TF, Wang PC, Yeh HI, Wang SW (2013) Butein inhibits angiogenesis of human endothelial progenitor cells via the translation dependent signaling pathway. Evid Based Complement Altern Med. https://doi.org/10.1155/2013/943187

Article  Google Scholar 

Gao Y, Rankin GO, Tu Y, Chen YC (2016) Theaflavin-3,3′-digallate decreases human ovarian carcinoma OVCAR-3 cell-induced angiogenesis via Akt and notch-1 pathways, not via MAPK pathways. Int J Oncol 48:281–292

Article  CAS  PubMed  Google Scholar 

Ueta T, Ishihara K, Notomi S, Lee J-J et al (1967) RIP1 kinase mediates angiogenesis by modulating macrophages in experimental neovascularization. Proc Natl Acad Sci U S A 116(47):23705–23713. https://doi.org/10.1073/pnas.1908355116

Article  CAS  Google Scholar 

Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA (2007) Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets 11:1587–1609

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao H, Liu L, Ma Y, Fang J, Fang W, Ma H, Zhang Y, Feng G, Hong S, Zeng S, Xie B, Ren J, Lin X, Zhang Y, Xi N, Jiang Y, Wu Y, Kang N, Li S, Zhang L (2020) A phase Ib study of a novel c-MET, AXL and VEGFR-2 inhibitor ningetinib and gefitinib combination therapy in Chinese EGFR-TKI resistant NSCLC with T790M negative. J Clin Oncol 38:9583

Article  Google Scholar 

Krishnamoorthy SK, Relias V, Sebastian S, Jayaraman V, Saif MW (2015) Management of regorafenib-related toxicities: a review. Ther Adv Gastroenterol 8:285–297

Article  CAS  Google Scholar 

Wang Z, Xu J, Nie W, Huang G, Tang J, Guan X (2014) Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. Eur J Clin Pharmacol 70:225–231

Article  CAS  PubMed  Google Scholar 

Ivanyi P, Eggers H, Hornig M, Kasper B, Heissner K, Kopp HG, Kirstein M, Ganser A, Grünwald V (2020) Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors. Mol Clin Oncol 13:1–5